OnKure Therapeutics, Inc. (OKUR)
NASDAQ: OKUR · Real-Time Price · USD
4.800
-0.100 (-2.04%)
At close: Apr 24, 2026, 4:00 PM EDT
5.01
+0.21 (4.38%)
After-hours: Apr 24, 2026, 7:30 PM EDT
← View all transcripts

AGM 2025

May 27, 2025

Nicholas Saccomano
President and CEO, OnKure Therapeutics

Good morning. The meeting is called to order. I'm Nick Saccomano, President, CEO, and a Director of OnKure Therapeutics, and I will act as Chair of the meeting. Rogan Nunn, our Corporate Secretary and General Counsel, will act as Secretary of the meeting and take minutes of the meeting. At this time, I would like to introduce the other directors in attendance: Michael Carruthers, Michael Grey, Valerie Jansen, Isaac Mankey, Edward Mathers, and Andrew Phillips. I would also like to introduce the other corporate officers who are in attendance: Jason Leverone, our Chief Financial Officer; Samuel Agreste, our Chief Medical Officer; and Dylan Hartley, our Chief Scientific Officer. Also with us today is Paul R. Ramirez, representing Broadridge Financial Solutions. I will now ask Mr. Nunn to make his report.

Rogan Nunn
Corporate Secretary and General Counsel, OnKure Therapeutics

Thank you. I have received an affidavit of mailing stating that the notice of internet availability of proxy materials was first sent or given on April 16th, 2025, to the stockholders of record as of the close of business on April 1st, 2025, the record date for the meeting. A copy of the affidavit will be filed with the minutes of the meeting. The Inspector of Elections for the meeting has signed an oath to execute faithfully the duties of Inspector of Elections at the meeting. A copy of the oath will also be filed with the minutes of the meeting. The Inspector of Elections has advised me that we have present, virtually or by proxy, a sufficient number of shares to constitute a quorum on all matters being presented at the meeting.

Nicholas Saccomano
President and CEO, OnKure Therapeutics

Thank you. This meeting is duly constituted, and we may proceed with business.

As set forth in the notice of internet availability of proxy materials, and further described in the proxy statement, the business of this meeting is to: one, elect two nominees to the company's board of directors as Class 1 directors, and two, ratify KPMG LLP as the company's independent registered public accounting firm. The first item of business is the election of two Class 1 directors to hold office until our 2028 annual meeting of stockholders and until their respective successors are elected and qualified. The nominees for election designated by our Board of Directors are Isaac Mankey and Nicholas Saccomano. Our Board of Directors recommends vote for the election of each of these nominees. The second item of business is to ratify the appointment of KPMG as our independent registered public accounting firm for the fiscal year ending December 31, 2025.

Our Board of Directors recommends a vote for the ratification of KPMG.

We will now proceed to the question and answer period. I remind you that the meeting has been called for the purpose of considering the items of business described above. Please confine your questions and comments to those matters. If anyone has any questions or comments regarding the proposals previously described, please submit your question or comment by inputting your questions into the Q&A text box on your screen and clicking Submit.

Rogan Nunn
Corporate Secretary and General Counsel, OnKure Therapeutics

Okay.

Nicholas Saccomano
President and CEO, OnKure Therapeutics

If there are no further questions or comments, we will now proceed with the voting. I direct the vote to be taken amongst all those who have not already voted upon the matters before the meeting or those revoking their prior votes and voting. The polls are now open at 7:03 Mountain Time.

Rogan Nunn
Corporate Secretary and General Counsel, OnKure Therapeutics

Please note that we will vote by proxy and by online ballot. Each holder of Class A Common Stock is entitled to one vote for each share held at the close of business on the record date. If you have turned in a proxy and do not intend to change your vote, then it is not necessary that you vote at this meeting because we will count your proxy. Those of you who did not turn in a proxy or who wish to change your vote may do so by clicking the Vote link on the website used to access this meeting and following the instructions. The votes cast today will be counted in the final tally along with the proxies previously received.

Nicholas Saccomano
President and CEO, OnKure Therapeutics

Now that everyone has had the opportunity to vote, I hereby declare the polls closed at 7:04 Mountain Time with respect to each matter to be voted on at this meeting.

Rogan Nunn
Corporate Secretary and General Counsel, OnKure Therapeutics

The Inspector will now tabulate the proxies and votes. At this time, I'm pleased to report that based on the current tabulation of votes, Mr. Mankey and Dr. Saccomano—sorry, that should be Dr. Mankey and Dr. Saccomano—have been elected as Class 1 directors, and the appointment of KPMG to act as the company's independent registered public accounting firm for the fiscal year ending December 31, 2025, has been ratified. These are the preliminary results of voting. The final count may vary following final examination of the votes. I direct that the report of the Inspector of Elections be filed with the minutes of the meeting. The final results will also be filed with the SEC on Form 8-K within four business days of today's meeting.

Nicholas Saccomano
President and CEO, OnKure Therapeutics

This concludes the meeting, and the meeting is now adjourned. Thank you.

Operator

The conference is now concluded. Thank you for attending. You may now disconnect.

Powered by